These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32725057)

  • 21. Combination therapy with benznidazole and doxycycline shows no additive effect to monotherapy with benznidazole in mice infected with the VL-10 strain of the Trypanosoma cruzi.
    Carneiro ACA; Costa GP; Ferreira CS; Ramos IPR; Sarandy MM; Leite ALJ; Menezes APJ; Silva BM; Nogueira KOPC; Carvalho ACC; Gonçalves RV; Talvani A
    Int J Cardiol; 2020 Jan; 299():243-248. PubMed ID: 31353153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of a patient since the acute phase of Chagas disease (South American trypanosomiasis): further treatment and cure of the infection.
    Dias JC; Dias E; Nóbrega GC
    Rev Soc Bras Med Trop; 2015; 48(5):629-32. PubMed ID: 26516979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
    Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and biodistribution of benznidazole in mice.
    Perin L; Pinto L; Balthazar Nardotto GH; da Silva Fonseca K; Oliveira Paiva B; Fernanda Rodrigues Bastos Mendes T; Molina I; Correa-Oliveira R; Melo de Abreu Vieira P; Martins Carneiro C
    J Antimicrob Chemother; 2020 Aug; 75(8):2213-2221. PubMed ID: 32356873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.
    Murcia L; Carrilero B; Ferrer F; Roig M; Franco F; Segovia M
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1819-1827. PubMed ID: 27488437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
    de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
    Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
    Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
    ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
    Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
    Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
    Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
    Cardoso CS; Ribeiro ALP; Oliveira CDL; Oliveira LC; Ferreira AM; Bierrenbach AL; Silva JLP; Colosimo EA; Ferreira JE; Lee TH; Busch MP; Reingold AL; Sabino EC
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006814. PubMed ID: 30383777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
    Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I
    Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
    Morilla MJ; Romero EL
    Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiological drug treatment of human infection by Trypanosoma cruzi.
    Levi GC; Lobo IM; Kallás EG; Amato Neto V
    Rev Inst Med Trop Sao Paulo; 1996; 38(1):35-8. PubMed ID: 8762637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.